CN1073946A - The method for preparing borate proline - Google Patents
The method for preparing borate proline Download PDFInfo
- Publication number
- CN1073946A CN1073946A CN92113215A CN92113215A CN1073946A CN 1073946 A CN1073946 A CN 1073946A CN 92113215 A CN92113215 A CN 92113215A CN 92113215 A CN92113215 A CN 92113215A CN 1073946 A CN1073946 A CN 1073946A
- Authority
- CN
- China
- Prior art keywords
- formula
- glycol
- boric acid
- pinane
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 94
- OHVALSOULVZORC-WCCKRBBISA-N B(O)(O)O.N1[C@H](C(=O)O)CCC1 Chemical compound B(O)(O)O.N1[C@H](C(=O)O)CCC1 OHVALSOULVZORC-WCCKRBBISA-N 0.000 title claims abstract description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 172
- XOKSLPVRUOBDEW-UHFFFAOYSA-N pinane Chemical compound CC1CCC2C(C)(C)C1C2 XOKSLPVRUOBDEW-UHFFFAOYSA-N 0.000 claims abstract description 124
- 239000004327 boric acid Substances 0.000 claims abstract description 98
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims abstract description 83
- 229930006728 pinane Natural products 0.000 claims abstract description 64
- -1 pinane glycol borate ester Chemical class 0.000 claims abstract description 59
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 37
- 125000006239 protecting group Chemical group 0.000 claims abstract description 30
- 150000002148 esters Chemical class 0.000 claims abstract description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 18
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 18
- 150000001413 amino acids Chemical class 0.000 claims abstract description 13
- 150000003233 pyrroles Chemical class 0.000 claims abstract description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 9
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000004185 ester group Chemical group 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 70
- 239000000243 solution Substances 0.000 claims description 56
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 150000002430 hydrocarbons Chemical group 0.000 claims description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 238000006138 lithiation reaction Methods 0.000 claims description 11
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical group [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 8
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 8
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 7
- 229950003188 isovaleryl diethylamide Drugs 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 230000032050 esterification Effects 0.000 claims description 6
- 238000005886 esterification reaction Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 4
- 239000003729 cation exchange resin Substances 0.000 claims description 4
- 238000005336 cracking Methods 0.000 claims description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 125000005647 linker group Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 2
- 239000000543 intermediate Substances 0.000 claims 24
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 238000005341 cation exchange Methods 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- 238000012856 packing Methods 0.000 claims 2
- LYSQGYSICZCRKO-UHFFFAOYSA-N boric acid;n,n-dimethylmethanamine Chemical compound CN(C)C.OB(O)O LYSQGYSICZCRKO-UHFFFAOYSA-N 0.000 claims 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 14
- 230000004224 protection Effects 0.000 abstract description 11
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 abstract description 9
- 102000004190 Enzymes Human genes 0.000 abstract description 8
- 108090000790 Enzymes Proteins 0.000 abstract description 8
- 229910052796 boron Inorganic materials 0.000 abstract description 8
- 125000005619 boric acid group Chemical group 0.000 abstract description 3
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 39
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 38
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 239000000463 material Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 15
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 229960001866 silicon dioxide Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000003513 alkali Substances 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000006219 Matteson homologation reaction Methods 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 3
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VGKZBAMIYUHSMU-UHFFFAOYSA-N 4-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylic acid Chemical compound OC(=O)C1CCC(NC(=O)N(CCCl)N=O)CC1 VGKZBAMIYUHSMU-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- TZHYBRCGYCPGBQ-UHFFFAOYSA-N [B].[N] Chemical compound [B].[N] TZHYBRCGYCPGBQ-UHFFFAOYSA-N 0.000 description 2
- 210000003323 beak Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- IZPYBIJFRFWRPR-UHFFFAOYSA-N tert-butyl pyrrole-1-carboxylate Chemical class CC(C)(C)OC(=O)N1C=CC=C1 IZPYBIJFRFWRPR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- 125000004747 1,1-dimethylethoxycarbonyl group Chemical group CC(C)(OC(=O)*)C 0.000 description 1
- YAXWOADCWUUUNX-UHFFFAOYSA-N 1,2,2,3-tetramethylpiperidine Chemical compound CC1CCCN(C)C1(C)C YAXWOADCWUUUNX-UHFFFAOYSA-N 0.000 description 1
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Substances CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 1
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- UHBXGHADNVDXMM-UHFFFAOYSA-N C(C)(C)N(C(C)C)CC[Li] Chemical compound C(C)(C)N(C(C)C)CC[Li] UHBXGHADNVDXMM-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- CBQJSKKFNMDLON-JTQLQIEISA-N N-acetyl-L-phenylalanine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CBQJSKKFNMDLON-JTQLQIEISA-N 0.000 description 1
- FULZLIGZKMKICU-UHFFFAOYSA-N N-phenylthiourea Chemical class NC(=S)NC1=CC=CC=C1 FULZLIGZKMKICU-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001361 allenes Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- PMPYSSMGWFNAAQ-UHFFFAOYSA-N dichloromethane;n,n-diethylethanamine Chemical compound ClCCl.CCN(CC)CC PMPYSSMGWFNAAQ-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- HYXDULZRFHVIDQ-UHFFFAOYSA-N ethyl acetate;methane Chemical compound C.CCOC(C)=O HYXDULZRFHVIDQ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 238000011905 homologation Methods 0.000 description 1
- 238000006197 hydroboration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- IZUFUXNHBBCTCA-UHFFFAOYSA-N lithium;1-methylpiperidine Chemical compound [Li].CN1CCCCC1 IZUFUXNHBBCTCA-UHFFFAOYSA-N 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- VQEVKEKJZVEGPH-UHFFFAOYSA-N lithium;chloromethane Chemical compound [Li+].Cl[CH2-] VQEVKEKJZVEGPH-UHFFFAOYSA-N 0.000 description 1
- HTZGVHYSMVGNOV-UHFFFAOYSA-N lithium;dicyclohexylazanide Chemical compound [Li+].C1CCCCC1[N-]C1CCCCC1 HTZGVHYSMVGNOV-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- DKTXXUNXVCHYDO-UHFFFAOYSA-N phenoxyborinic acid Chemical compound OBOC1=CC=CC=C1 DKTXXUNXVCHYDO-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- WGLLSSPDPJPLOR-UHFFFAOYSA-N tetramethylethylene Natural products CC(C)=C(C)C WGLLSSPDPJPLOR-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- AJSTXXYNEIHPMD-UHFFFAOYSA-N triethyl borate Chemical compound CCOB(OCC)OCC AJSTXXYNEIHPMD-UHFFFAOYSA-N 0.000 description 1
- MDCWDBMBZLORER-UHFFFAOYSA-N triphenyl borate Chemical compound C=1C=CC=CC=1OB(OC=1C=CC=CC=1)OC1=CC=CC=C1 MDCWDBMBZLORER-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Introduced a kind of method for preparing borate proline.By lithiumation, its product and trialkyl borate react the protected pyrroles of N-in the 2-position.Again it is reduced to form protected proline(Pro) boric acid, make it then to react to obtain ester with glycol.Along with the boric acid part with the ester group protection is removed the protecting group on the nitrogen, with the borate proline that need to obtain.The borate proline that makes in interchangeable synthesizing has a chiral centre on the boron atom.The method that enantiomorph splits is also disclosed, to obtain having borate proline rather than a kind of amino acid whose peptide at the C-end group.These boric acid peptide analogs can be used for suppressing important protein enzyme biologically.Several methods of removing the pinane glycol from the pinane glycol borate ester are also disclosed.
Description
The present invention relates to a kind of method for preparing the borate proline of optically-active.These esters can be used as the intermediate of producing peptide and combine with proline(Pro) boric acid rather than proline(Pro).These peptides can be used to suppress the various enzymes of important protein biologically.
Holding residue as the peptide with the boric acid analogue that mixes a-amino acid to substitute C-, has been reports of effective inhibitor of many serine proteases based on these compounds, makes people produce interest to the boric acid analogue of a-amino acid.For example, referring to people such as Matteson [J.Am.Chem.Soc.103,5241(1981)]; People such as Kettner [J.Biol.Chem.259,15106(1984)]; With people [J.Med.Chem.27,1919(1985)] such as Kinder.
Some investigators, comprise people such as Koehler [Biochemistry, 10,2477(1971)] and people [Biochemistry such as Rawn, 13,3124(1974)], infer that the P track of the sky of the former subcenter of boron acts on mutually with the zymophore hydroxyl in these compounds, formed the tetrahedron adducts of the transition state of an analog enzyme hydrolysis.Can imagine that the boric acid analogue is more tight to the binding ratio substrate of enzyme itself, thereby suppress enzymatic activity substrate.Because the boric acid analogue of a-amino acid is luminous based on the biological function of the enzyme that they suppressed with the Toplink of mixing these analogues, so just be used at present in the research.In addition, explain that they also can be used in the treatment just as following.
Because being presented at the peptide that the C-end group is combined with the alpha-amino boronic acid analogue (BoroPro) of proline(Pro) is effective inhibitor of some postproline cleavage enzyme, be interested especially therefore.For example, people such as Bachovchin [J.Biol.Chem.265,3738(1990)] report the inhibitor that this class peptide is the IgA proteolytic enzyme that obtains from some bacterium.These enzymes are participated in bacterium toxicity consumingly.People such as Flentke [Proc.Natl.Acad.Sci.USA88,1556(1991)] report this class peptide and suppress dipeptidyl peptidase IV (DP-IV), and the latter then plays restraining effect to the cell proliferation and the IL-2 generation of antigen induction in the T-cell.Known back one effect causes immunoreactive inhibition.Immunoreactive being suppressed at handled as being useful in organ-graft refection, graft versus host disease and the various autoimmune disease.
The synthetic route of alpha-amino boronic acid in the past depends on the disclosed steps of people such as aforesaid Mattesont, and it follows hydroboration, carries out the response hierarchy that (asymmetric) homologation and ammonia are separated with the chloromethyl lithium.People such as Matteson [Organometallics 3,1284(1984)] have described and have utilized this technology to synthesize N-ethanoyl L-Ala, N-ethanoyl Xie Ansuan, the method for the boric acid analogue of N-ethanoyl leucine and N-acetyl phenyl alanine.Some are arranged in these analogues, and (9: 1) non-mapping foreign body object ratio obtains with preferably.
Utilize the synthetic BoroPro of method of Matteson to be confirmed by aforesaid Bachovachin and Flentke, need to make up pyrrolidine ring, therefore can only abandon but further modify.In addition, the reaction conditions that utilizes asymmetric synthesis or disassemble technique to prepare the BoroPro of single enantiomer yet there are no report.
Owing to the effective way that lacks proline biosynthesis boric acid has hindered further exploration postproline cleavage enzyme, the particularly biological chemistry of DP-IV, and the effort of using BoroPro base enzyme inhibitors to treat.
Needs to the better source of BoroPro impel us to explore this compound, the alternative synthetic route of the optical activity form of this compound particularly, and finished the present invention.
First big aspect of the present invention comprises the method for three proline biosynthesis boric acid esters that are closely related.Wherein two are begun by the pyrroles, and the 3rd synthetic method begun by tetramethyleneimine.In the scope of a first aspect of the present invention, comprise the intermediate that some are new.Proline(Pro) boric acid has a α chiral centre on the boron atom.Second big aspect of the present invention comprises a kind of method that splits proline(Pro) boric acid enantiomorph when needed.According to the method, by with a chiral alcohol, especially preferably react to generate borate proline with the pinane glycol.Separate the non-enantiomer mixture of introducing additional chiral centre generation and can finish the fractionation of enantiomorph easily.The borate proline that obtains can be at an easy rate and those activatory, as carbonyl acid groups phase coupling commonly used in peptide is synthetic, and obtaining having borate proline at the C-end group, rather than amino acid whose peptide.Can remove the ester protecting group to obtain free boric acid peptide.When the ester protecting group is the pinane glycol, be not easy to remove it with known technology.The 3rd aspect of the present invention comprises several methods of removing pinane glycerol protection base.
Fig. 1 is the preferred reaction scheme example of the present invention.
First synthetic method that begins with the pyrroles according to the present invention is to react with a kind of activatory carbonic acid derivatives, protects nitrogen-atoms so that utilize suc as formula the group of-COOR, and R is C in the formula
1-6Alkyl, C
3-6Cycloalkyl, benzyl, phenyl, by one or more C
1-6The phenyl that alkyl replaces, or trimethyl silyl ethyl are to obtain the compound suc as formula I.
R is the tertiary butyl, benzyl, trimethyl silyl ethyl, phenyl, methyl or ethyl in the better protecting group.Best protecting group is tertbutyloxycarbonyl or Boc.Can utilize known technology to use blocking group.People such as Grehn [Angew.Chem.Int.Ed.Engl.23.296, (1984)] have described the synthetic of 1-Boc-pyrroles.
Handle formula I compound to obtain compound with lithiation reagent subsequently suc as formula II
R is as previously defined group in the formula.
The lithiumation of formula I compound can be handled with known method with the methyl piperidine lithium and finish, as people such as Hasan [J.Org.Chem.46.157(1981)] introduce, or finish with other steric hindrance lithium amide such as diisopropylaminoethyl lithium or dicyclohexyl lithium amide, also can when having Tetramethyl Ethylene Diamine to exist, carry out lithiation with n-Butyl Lithium.This reaction can be carried out in inert solvent easily, is preferably temperature ether such as THF at-78 ℃~-40 ℃, diethyl ether, the solvent that glycol dimethyl ether or methyl tertiary butyl ether are such.Also available known as people such as Chen [Org.Syn.70.151(1991) method described with pyrroles's bromination, and protects resulting product on the 2-position, select for use as n-Butyl Lithium so not really the lithiation reagent of costliness to carry out lithiumation with known technology then.
Need not separate can be with the intermediate and the trialkyl borate reaction of formula II; wherein each alkyl can be the straight chain that contains 1~6 carbon atom; side chain or cycloalkyl; be preferably boric acid trimethylammonium ester or triethyl ester; carry out acid-catalyzed hydrolysis with the weak acid as citric acid or acetate or sal enixum so then, to obtain the pyrroles who has protecting group-2-boric acid suc as formula III
R is defined as the front in the formula.
Through catalytic hydrogenation formula III intermediate is reduced then, to form the proline(Pro) boric acid of protected formula IV.
The B definition is ditto described in the formula.
Formula III intermediate can use in the organic solvent as ethyl acetate or tetrahydrofuran (THF) as 5% platinum on the gac, platinum oxide, rhodium on the gac, the rhodium on the alumina, the such catalyzer of palladium on the gac or Raney Ni are under atmospheric pressure or carry out catalytic hydrogenation under the pressure of about 50psi.
A selectable synthetic method of the boric acid of formula IV is to handle tetramethyleneimine with a kind of suitable acylating reagent, to obtain protected compound suc as formula VIII.
R is defined as the front in the formula.
Select protecting group so that the activity of tetramethyleneimine can be carried out lithiumation in the position of contiguous nitrogen, protecting group should contain can hinder the huge part that lithiation reagent is attacked carbonyl.Preferably use the formamyl protecting group suc as formula-COOR, for example, R is tert.-butoxy or 2,4 in the group, 6-three-tertiary butyl phenoxy group.But also can use some acyl group or benzoyl group, as tertiary butyl carbonyl or trityl carbonyl.People such as Beak [Chem.Rev.84,471-523, (1984)] have described other suitable protecting group.Best protecting group is among tert-butoxycarbonyl or the Boc.Can protecting group be used for tetramethyleneimine by known technology.
Handle formula VIII compound to obtain formula IX compound with lithiation reagent subsequently.
R is defined as the front in the formula.
Formula VIII compound can be handled by known method with s-butyl lithium and Tetramethyl Ethylene Diamine and carry out lithiumation (described as people such as Beak [Tet.Lett.30.1197(1989)]).This reaction can be preferably a kind of ether such as diethyl ether easily in a kind of inert organic solvents, among methyl tertiary butyl ether or the THF, be approximately-78 ℃~0 ℃ in temperature, is preferably under-78 ℃~-40 ℃ the condition to carry out.Carry out lithiation with a reactive lithium alkylide such as s-butyl lithium or tert-butyl lithium, be preferably exist a kind of as Tetramethyl Ethylene Diamine, hexamethylphosphoramide or N, the N '-such coordination additive of dimethyl allene urea (DMPU).
Need not separate, formula IX intermediate then reacts with trialkyl borate, and wherein each alkyl can be the straight chain that contains 1~6 carbon atom, and side chain or cycloalkyl are preferably boric acid trimethylammonium ester or triethyl ester; Water is hydrolyzed and is extracted in the alkali aqueous solution as sodium hydroxide or potassium hydroxide to help purifying subsequently.Acidizing alkali solution is to about pH3, and extraction obtains the protected proline(Pro) boric acid suc as formula IV.
In order to form boric acid ester, the free boric acid intermediate that then makes the formula IV carries out esterification with glycol suc as formula V
X is a linking group in the formula, to obtain the compound suc as formula VI
X is and identical connection base above-mentioned in the formula, and R is defined as the front.So the ester group that forms is a kind of removable protecting group.The structure of this ester protecting group, synthetic be connected and the method for removing is generally known in chemical field.Therefore, the professional in the chemical field can be appreciated that the structure that connects basic X is unimportant.Connecting basic X can be 2 to 3 yuan of saturated hydrocarbon chains; Constitute and optionally contain unsaturated chain or condensed ring C
5-122 to 3 yuan of saturated hydrocarbon chains of the part of carbocyclic ring system; Constitute 2 to 3 yuan of hydrocarbon chains of the part of aromatic ring; Or suc as formula-(CH
2)
n-NH-(CH
2)
m-group, wherein n and m all 2 or 3; Wherein these groups can be unsubstituted or by one or more C
1-3Alkyl or phenyl replaces.
Correspondingly, be suc as formula the suitable glycol of V, for example, ethylene glycol, quite any alcohol, pyrocatechol, pinane glycol, fourth-2,3-glycol, 2,2-dimethyl propylene-1,3-glycol, diethanolamine and 1,2-phenylbenzene second-1,2-glycol.
For the boric acid part by ester group protection, available then known technology is removed protecting group on the denitrification (as Greene at " Protective Groups in Organic Synthesis " (J.Wiley; Sons, 1981) described in); To obtain hydrochloride suc as formula the required borate proline of VII.
For example, when protecting group was Boc, the dried hydrogenchloride that can be used at an easy rate in the ethyl acetate was removed.
Be preferably formula IV compound and a kind of chirality, non-racemic glycol are carried out esterification, these glycol are as (1S, 2S, 3R, 5S)-(+) pinane glycol), 1,2-phenylbenzene second-1,2-glycol; Or fourth-2, the 3-glycol; Because can in molecule, introduce additional chiral centre like this.Can utilize known diastereomer separation method like this, as the α chiral centre on HPLC or the fractionation crystallization fractionation boron atom.This point has illustrated in the reaction scheme figure of Fig. 1, in the isomers of formula VI compound with (1S, 2S, 3R, 5S)-(+)-boric acid of pinane glycerol protection can separate with high pressure liquid chromatography (HPLC) method (HPLC), obtains compound VI a and VI b.In addition; hydrochloride isomer with formula VII compound of same boron protecting group can be at solvent (as ethyl acetate; or dichloromethane/ethyl acetate mixture; Virahol or ethanol) in separate with fractionation crystallization, to obtain being connected carbon on the boron individual isomer compound VII b of R configuration is arranged.
Another benefit of using the pinane glycol is that the boric acid ester that so forms is more stable than the ester that obtains with other glycol, for example, often observes in chromatography when quite which is pure and has lost a large amount of protecting groups.Owing to can obtain the better rate of recovery of required material, this method is of great use carrying out in purifying and the isomer separation with silica gel column chromatography.
In the above-mentioned synthetic method that makes improvements slightly, the pyrrole derivative of formula III can be directly carries out esterification with the glycol of formula V, obtains the ester of formula III A.
This ester can reduce with the method identical with formula III compound, produces the protected borate proline suc as formula VI.In other words, promptly can put upside down pyrrole ring in reactions steps is reduced and the esterified order of boronate.
Zhi Bei borate proline is easy to and activatory carboxylic acid commonly used in peptide is synthetic like this, and for example, the protected amino acid coupling of a kind of nitrogen is to obtain the compound suc as formula X
In the formula-COOR
2Be a kind of amino protecting group commonly used in peptide is synthetic, so R
2Be, for example, the tertiary butyl, benzyl or fluorenyl methyl, R
3Be naturally occurring amino acid whose side chain, can have the sort of suitable protecting group commonly used in peptide is synthetic.
Formula X compound contains protecting group on boric acid and amino acid nitrogen.In order to keep biologic activity or, one of them or two protecting groups can be removed in case of necessity for further chemical treatment.Can remove protecting group by arbitrary order.The whole bag of tricks of removing these protecting groups is described below.
Available known method is removed nitrogen-protecting group, to obtain the compound of formula XI.
The ester group of protection boric acid part is stable in neutral or acid organic medium, but the cracking and produce boric acid rapidly under alkali (pH=7.5) aqueous conditions of gentleness of many boric acid esters.Yet, under the boric acid ester situation of using the pinane glycol, known its hydrolysis is difficult, and need specific conditions to remove the pinane glycol, for example, referring to people [J.Organometallic Chem.385,15(1988)] such as people such as Matteson [J.Am.Chem.Soc.102,7590(1980)] and Brown.
These methods are unsuitable for removing the pinane glycol in the compound of X or XI from suc as formula VI.We have found that some are used for removing the method for pinane glycol in the boric acid ester compound of X or XI from suc as formula VI.Therefore, the removal of pinane glycol can use a kind of oxygenant with cracking 1,2 glycol ability to carry out under mild conditions, to remove the pinane glycol and balance is further moved to free boric acid direction from balance.For example, handling protecting group with sodium metaperiodate under room temperature in ammonium acetate solution and acetone is the compound of the formula VI and the formula X of pinane glycol, obtains the compound of formula IV and formula XII respectively.
This reaction can be carried out in water easily, can add the buffered soln as ammonium acetate or Sodium phosphate dibasic, pH is between 3~10, be preferably 6 to 8, temperature is 0 to 80 ℃, be preferably 20 to 40 ℃, can have a kind of as acetone, methyl alcohol, ethanol, tetrahydrofuran (THF) (THF) or acetonitrile etc. can be miscible with water organic solvent.Suitable oxygenant is to have to decompose 1, the non-nucleophilicity oxygenant of 2-glycol ability such as Periodic acid or its salt or permanganate.Do not find the oxygenolysis of carbon one boron key under these conditions, be appreciated that this method is applicable in any boric acid with the pinane glycerol protection.In addition, it also can be used for anyly belonging to 1, and in the boric acid ester protecting group of 2-glycol, and when to the simple aqueous hydrolytic action of protecting group when very slow or incomplete, this method is particularly useful.
Contain the pinane glycol borate ester compound of the amine of not protection in use, during suc as formula the XI compound, also can use aforesaid method, but more desirable to second kind of novel method of such compound.This method be included in pH4 or the cation exchange resin column of formula XI compound water solution being packed into when lower in, water or this post of dilute acetic acid wash-out are to remove the pinane glycol.Can from balance, remove the pinane glycol like this and reaction is moved to the hydrolysis direction.Then with rare this post of ammonium hydroxide aqueous solution wash-out removing product, obtain the salt of formula X III compound after evaporation and the acidifying
Be to use a kind of strong-acid cation-exchange resin aptly, as sulfonic resin, Dowex50 for example, the pinane glycol of wash-out can reclaim from the aqueous solution and reuse from resin, this can pass through a nonionic superpolymer sorbent material with the aqueous solution easily, as can almost quantitatively adsorbing the Amberlite of pinane glycol
The XAD-200 post is finished.The pinane glycol can be removed from post with methyl alcohol or ethanol elution.Ion-exchange and pinane glycol adsorb this two steps operation and can be attached in the process, with pump water are recycled to another pillar from a pillar in this process.Have the still less advantage of water gaging like this, and can make process continuously to sufficiently long to obtain higher product yield.
One of skill in the art can understand that the above-mentioned method of utilizing a kind of Zeo-karb to remove the pinane glycol only is suitable for containing the alkaline functional base, as the compound of unprotected amine.
The third method also is suitable for containing the compound of not protecting amine, suc as formula the pinane diol ester of XI compound.This method is included in the two-phase system and uses formula R
4-B(OH)
2Another boric acid carry out the transesterification of pinane glycol borate ester, R in the formula
4Represent the alkyl of a C1-12, it can be by straight chain, and side chain or cycloalkyl chain and phenyl ring are formed, preferred R
4It is phenyl.In the two-phase one is that pH adjusts to and is lower than 7 mutually, is preferably the water of pH1-4, and another is as hexane mutually, the hydrocarbon organic solvent that sherwood oil or toluene are such.Therefore, in the water of pH1 and hexanes mixtures, handle formula XI compound, by being separated, in organic phase, produce the pinane diol ester of phenyl-boron dihydroxide subsequently, it can be reclaimed through evaporation with phenyl-boron dihydroxide; And at the solution of the free boric acid of aqueous phase production X III, spent ion exchange resin with above-mentioned similar methods can be with this solution separating.The unique component that is dissolved in this system in the organic phase is a pinane glycol phenyl boronate, thereby has removed the pinane glycol from balance; The formula X III compound of formula XI compound and formation is because the two all is insoluble to varsol, so they are stayed in the water layer.Available any boric acid that has the alkyl side chain reacts, and generates the pinane diol ester that is dissolved in the varsol.
The also available known method of complete de-protected formula X III compound is removed nitrogen-protecting group and is prepared from formula XII compound.As can be seen suc as formula X, XI, the compound of XII and X III has two chiral centres usually.A contiguous boron atom, another is present in the amino acid moiety, when this part makes an exception during for glycine.Also can see,, compare the pure single diastereomer that more needs these compounds with the non-enantiomer mixture of these compounds for biological applications.Therefore it is very important to prepare the pure individual isomer of these compounds.The most important thing is that because amino acid may exist with the single enantiomer form usually, this purpose can be with known technology by making the coupling and separate formed non-enantiomer mixture and reach mutually of optically pure amino acid and racemize proline(Pro) boric acid.Yet, have been found that these Special Circumstances of Xie Ansuan only, this class separate often be difficulty with time taking.Therefore better being to use a kind of chiral centre that is close to the boron atom is the proline(Pro) boric acid of individual isomer, at this moment with after the coupling of optically-active pure amino acid need not carry out the fractionation of isomer.The invention provides a kind of method that is easy to be used to split proline(Pro) boric acid enantiomorph.
The following example further illustrates the present invention.
Embodiment 1
1-(1,1-dimethyl ethoxy carbonyl)-pyrroles-2-boric acid
To tetrahydrofuran (THF) (THF) (275ml) under-78 ℃ of argon shields tetramethyl piperidine (8.8ml, 52mmol) add in the solution 2M solution of butyllithium in ethane (26ml, 52mmol).In above-mentioned solution, be added in THF(10ml after 15 minutes) in 1-(1,1-dimethyl ethoxy carbonyl)-pyrroles (8.35g, 50mmol) solution, and stirred 4 hours down at-78 ℃.(30ml 176mmol), and made mixture rise to room temperature through 3 hours, again after 12 hours, with ether (500ml) diluted reaction mixture and use 1M KHSO to add triethyl borate then
4The aqueous solution wash (3 * 100ml), use 1M NaHCO then
3The aqueous solution wash (1 * 100ml), use MgSO
4Drying gets brown solid through rotary evaporation, and it is used flash chromatography method purifying (1: 9 ethyl acetate: hexane), obtain 8.7g(82%) white crystalline solid (101.0~101.5 ℃ of fusing points) on silica gel.
1H NMR(CDCl
3): δ 1.65(s, 9H), and 6.26(t, J=3.3(Hz, 1H), and 7.10(dd, J=1.6,3.2Hz, 1H), 7.15(s, 2H), and 7.44(dd, J=1.6,3.2Hz, 1H); 13C NMR(CDCl
3) 27.9,85.5,112.0,128.7,152.0; CIMS m/z(% relative intensity) 212(MH+, 11), 156(100), 138(68); Ultimate analysis: C
9H
14BNO
4Calculated value: C, 51.23, H, 6.69, N, 6.64. measured value: C, 51.22, H, 6.51, N, 6.67.
Embodiment 2
1-(1,1-dimethyl ethoxy carbonyl)-tetramethyleneimine-2-boric acid
6.15 gram (24mmol) is as 1-(1 of embodiment 1 preparation, 1-dimethyl ethoxy carbonyl)-the solution 5%pt/c(ca.500mg of pyrroles-2-boric acid in ethyl acetate (100ml)) hydrogenation 24 to 48 hours under 50psi.The suspension of gained filters and concentrates through Celite pad.This material carries out chromatography with silica gel, and used continuous elutriant is 9: 1 hexanes: ethyl acetate is acetone then, and the concentrated trace solvent post crystallization of removing of partial acetone is gone out limpid glassy required compound 6.05 gram (97%) (100~101 ℃ of fusing points).
1H NMR(CDCl
3): δ 1.42(s, 9H), 1.6-2.15(m, 5H), 3.1-3.6(m, 2H);
13C NMR(CDCl
3) δ 25.1,25.7,28.4,45.6,46.2,78.6,154.5; CIMS m/z(% relative intensity) 116(100), 70(46); Ultimate analysis: C
9H
18BNO
4Calculated value: C, 50.27, H, 8.44, N, 6.51.
Measured value: C, 50.52, H, 8.22, N, 6.58.
Embodiment 3
(1S, 2S, 3R, 5S)-pinane glycol 1-(1,1-dimethyl ethoxy carbonyl-tetramethyleneimine-2S-boric acid ester and (1S, 2S, 3R, 5S)-pinane glycol 1-(1,1-dimethyl ethoxy carbonyl)-tetramethyleneimine-2R-boric acid ester
Press the 1-(1 of embodiment 2 preparations, 1-dimethyl ethoxy carbonyl)-tetramethyleneimine-2-boric acid (1.52g, 7.1mmol) solution and (1S, 2S, 3R, 5S)-(+)-(1.36g 8.0mmol) stirred under the room temperature 2 hours in ether (25ml) the pinane glycol, concentrated and through flash chromatography on silica gel (85: 15 hexanes: ethyl acetate) obtain the mixture of two kinds of diastereomers of 2.1 grams (85%) 1: 1 ratio.They carry out HPLC through the porous silica gel A post of a 300 * 3.9mm and separate, and use methyl tertiary butyl ether: hexane (1: 9) wash-out and usefulness U.V detector are in the detection of 220nm place.Under these conditions at first wash-out be isomer (1S, 2S, 3R, 4S, 5S)-pinane glycol 1-(1,1-dimethyl ethoxy carbonyl)-tetramethyleneimine-2S-boric acid ester.
The S-isomer:
1H NMR(C
6D
6): δ 0.55(s, 3H), 1.09(s, 3H), 1.52(s, 9H), 1.60(s, 3H), 1.2-2.2(m, 8H), 3.1-3.5(m, 3H), 4.11(m, 0.3H), 4.33(m, 0.7H);
13C NMR(C
6D
6): δ 23.9,26.6,27.1,27.3,28.4,28.6,28.8,36.0,38.2,39.9,46.1,51.9,78.3,78.5,85.7,154.9.
The R-isomer:
1H NMR(C
6D
6): δ 0.52(s, 3H), 1.08(s, 3H), 1.52(s, 9H), 1.61(s, 3H), 1.2-2.2(m, 8H), 3.1-3.6(m, 3H), 4.01(m, 0.3H), 4.25(m, 0.7H);
13C NMR(C6D6) 23.9,26.6,27.1,27.3,28.4,28.7,28.9,35.8,38.2,39.6,46.2,51.8,78.1,78.5,85.7,154.5.
Can clearly be seen that, with (1R, 2R, 3S, 5R)-(-)-the pinane glycol makes raw material and can prepare (1R, 2R, 3S with similar method, 5R)-pinane glycol-1(1, the 1-dimethyl ethoxycarbonyl)-tetramethyleneimine-2S-boric acid ester and (1R, 2R, 3S, 5R)-and pinane glycol-1-(1, the 1-dimethyl ethoxycarbonyl)-tetramethyleneimine-2R-boric acid ester.
Embodiment 14
(1S, 2S, 3R, 5S)-pinane glycol tetramethyleneimine-2S-boric acid ester hydrochloride
Press (1S, 2S, 3R, 5S)-pinane glycol-1-(1,1-dimethyl ethoxy carbonyl)-tetramethyleneimine-2S-acid ester solution (28.5mg, the 0.08mmol) stirring in the EtoAc of anhydrous HCl solution (about 3M) of embodiment 3 preparation.This solution concentrates 2 times to produce 21.2 milligrams (91%) required white salt acidifying thing solid (molten 204 ℃ (decomposition)) after 2 hours from ethyl acetate.
1H NMR(CDCl
3): δ 0.83(s, 3H), and 1.14(d, J=11Hz, 1H), 1.29(s, 3H), 1.45(s, 3H), 1.85-2.15(m, 6H), 2.17-2.50(m, 3H), 3.18-3.25(m, 1H), 3.45(bs, 2H), 4.42(dd, J=1.8,8.6Hz, 1H), 8.80(bs, 1H), 10.56(bs, 1H);
13C NMR(CDC
13): δ 23.9,24.5, and 26.5,27.0,27.2,28.4,34.9,38.2,39.4,45.8,51.2,79.0,87.6; CIMS m/z(% relative intensity) 250(MH+, 1000); HRMS(EI): C
14H
24BNO
2Calculated value 249.1900, measured value 249.1899.
As can be seen with similar method can prepare (1S, 2S, 3R, 5S)-pinane glycol-tetramethyleneimine-2S-boric acid ester hydrochloride.
Embodiment 5
(1S, 2S, 3R, 5S)-pinane glycol tetramethyleneimine-2R-boric acid ester hydrochloride
Press (the 1S of embodiment 3 preparations, 2S, 3R, 5S)-pinane glycol-1-(1,1-dimethyl ethoxy carbonyl)-tetramethyleneimine-2R-acid ester solution (18.3mg, 0.05mmol) handle with the anhydrous HCl among the aforesaid EtoAc, back acquisition 14.3mg(96% is finished in experiment) required white salt acidifying thing solid (fusing point 248 ℃ (decomposition)).
1H NMR(CDCl
3): δ 0.83(s, 3H), and 1.14(d, J=11Hz, 1H), 1.29(s, 3H), 1.45(s, 3H), 1.85-2.15(m, 6H), 2.17-2.50(m, 3H), 3.18-3.25(m, 1H), 3.45(bs, 2H), 4.42(dd, J=1.8,8.6Hz, 1H), 8.80(bs, 1H), 10.56(bs, 1H);
13C NMR(CDCl
3) δ 23.9,24.5,26.5,27.0,27.2,28.5,34.9,38.1,39.4,45.8,51.2,79.0,87.8; CIMS m/z(% relative intensity) 250(MH+, 100); HRMS(EI): C
14H
24BNO
2Calculated value 249.1900, measured value 249.1903.
As can be seen with similar method can prepare (1R, 2R, 3S, 5R)-pinane glycol-tetramethyleneimine-2R-boric acid ester hydrochloride.
Embodiment 6
(1S, 2S, 3R, 5S)-and pinane glycol-1-(1,1-dimethyl ethoxy carbonyl)-pyrroles-2-boric acid ester
Press the 1-(1 of embodiment 1 preparation, 1-dimethyl ethoxy carbonyl)-pyrroles-2-boric acid solution (1.36g, 6.45mmol) and (1S, 2S, 3R, 5S)-(+)-(1.10g 6.45mmol) stirred 4 hours in the 20ml ether pinane glycol.Rotary evaporation is flash chromatography (95: 5 hexanes: ethyl acetate), obtain 1.83 gram (82%) required limpid oily products on silica gel then.
1H NMR(CDCl
3): δ 0.90(s, 3H), 1.30(s, 3H), 1.41(d, J=11Hz, 1H), 1.50(s, 3H), 1.50(s, 3H), 1.59(s, 9H), 1.96(m, 2H), and 2.21(t, J=6Hz, 1H), 2.16-2.40(m, 2H), 4.45(dd, J=2,8Hz, 1H), 6.20(t, J=3Hz, 1H), 6.65(d, J=3Hz, 1H), 7.40(d, J=3Hz, 1H);
13C NMR(CDCl
3): δ 24.0,26.4, and 27.2,28.1,28.6,35.5,38.3,39.8,51.8,79.8,83.6,83.9,111.6,123.2,124.7,150.0; CIMS m/z(% relative intensity) 346(MH+, 4), 246(81), 153(100), 135(56).
Can prepare with similar method as can be seen (1R, 2R, 3S, 5R)-and pinane glycol-1(1,1-dimethyl ethoxy carbonyl)-pyrroles-2-boric acid ester.
Embodiment 7
From 1-(1,1-dimethyl ethoxycarbonyl)-tetramethyleneimine prepares 1-(1,1-dimethyl ethoxy carbonyl)-tetramethyleneimine-2-boric acid
To the 1-(1 under-78 ℃ of nitrogen protections; 1-dimethyl ethoxy carbonyl)-tetramethyleneimine (17.1g; 100mmol) add in the solution in Anaesthetie Ether (200ml) solution of 1.3M s-butyl lithium in hexanaphthene (92.3ml, 120mmol) in, keep temperature to be lower than-60 ℃ simultaneously.After adding reaction mixture was stirred 4 hours down at-78 ℃.(31.1g 300mmol), made mixture temperature rise to room temperature through 3 hours to add boric acid trimethylammonium ester.After 12 hours, add entry (150ml) again, add 2M NaOH(200ml subsequently).Water phase separated is also used 2M NaOH(150ml) extracted organic phase once more.(5 * 200ml) extract the alkaline extraction liquid that merges with 2M HCl acidifying to pH3 and with ethyl acetate.With the organic extract drying (Na that merges
2SO
4) and concentrate to form required white crystalline solid product (15.49g, 72%), the material that itself and embodiment 2 produce is identical.
Embodiment 8
(1S, 2S, 3R, 5S)-and pinane glycol-1-(1, the 1-dimethyl ethoxycarbonyl)-tetramethyleneimine-2RS-boric acid ester
To the material that makes by embodiment 7 (15.49g, 72.0mmol) add in the solution in chloroform (250ml) (1S, 2S, 3R, 5S)-(+)-the pinane glycol (12.77g, 7.5mmol).After stirring 16 hours under the room temperature nitrogen protection, remove and desolvate; with flash chromatography on silica gel method (hexane/ethyl acetate 9: 1; 4: 1) the purifying residuum; obtain required oily non-enantiomer mixture (23.6g in 1: 1 ratio; 67.7%; press 1-(1,1-dimethyl ethoxy carbonyl)-the tetramethyleneimine meter).The isomer mixture that this material and embodiment 3 make is identical.
1H NMR(CDCl
3): δ 0.85(s, 3H), 1.12-1.21(m, 1H), 1.29(s, 3H), 1.41(s, 3H), 1.45(s, 9H), 1.81-2.20(m, 8H), 2.28-2.39(m, 1H), 3.04-3.18(m, 1H), 3.34-3.45(m, 2H), 4.28-4.38(m, 1H);
13C NMR(CDCl
3): δ 23.7,26.2, and 27.1,28.5,35.5,38.2,39.6,46.1,78.0,78.8,85.7,85.8,154.7; CIMS m/z(% relative intensity) 350(MH+, 100), 294(72), 250(30).
Embodiment 9
(1S, 2S, 3R, 5S)-analytical procedure of pinane glycol-tetramethyleneimine-2-boric acid ester hydrochloride diastereomer
The reagent solution of preparation 0.2M thiocarbanil in methylene dichloride-triethylamine (9: 1).Analyzed sample (1-5mg) is handled with reagent solution by the amount of every micromole's assay 10 microlitre reagent solutions, and clear liquid was placed 15 minutes in room temperature.Then, 1 microlitre solution example is analyzed (post: YMCAQ-303 S-5 120A, 4.6 * 250mm with 1.00 milliliters of high pressure liquid chromatography (HPLC) level dilution in acetonitrile, the solution after 10 microlitres dilute like this with the high pressure liquid chromatography (HPLC) method, moving phase: 65%MeCN-35% 25mM ammonium phosphate, pH7.5; Flow velocity 1ml/ branch detects at the 254nm place with UV).Wash-out goes out the phenylthiourea derivative of proline(Pro) boric acid R isomer in the time of about 6.4 minutes, and wash-out goes out its epimer in the time of about 7.8 minutes, as the unreacted thiocarbanil of internal standard then 12.2 minutes the time wash-out come out.
Embodiment 10
(1S, 2S, 3R, 5S)-pinane glycol tetramethyleneimine-2RS-boric acid ester hydrochloride
(1S, 2S, 3R with ice-cooled stirring, 5S)-pinane glycol-1-(1,1-dimethyl ethoxy carbonyl)-(224g, the 0.64mmol) solution in diethyl ether (900ml) fed solution 35 minutes with anhydrous HCl gas to tetramethyleneimine-2RS-boric acid ester under 10~18 ℃.Solution at room temperature stirs and spends the night, once more with ice-cooled and filter out throw out.Solid is washed then with sherwood oil/diethyl ether 9 with cold diethyl ether (400ml): 1(200ml) wash and vacuum-drying, obtain (fusing point 228-234 ℃ of required white salt acidifying thing solid (113g, 62%).Analyze this material with the high pressure liquid chromatography (HPLC) method described in the embodiment 9, prove that it is a R:S mixture of isomers by the boric acid of 60: 40 mixed.
1H NMR(CDCl
3): δ 0.83(s, 3H), and 1.14(d, J=11Hz, 1H), 1.29(s, 3H), 1.45(s, 3H), 1.85-2.15(m, 6H), 2.17-2.50(m, 3H), 3.18-3.25(m, 1H), 3.45(bs, 2H), 4.42(dd, J=1.8,8.6Hz, 1H), 8.80(b, 1H), 10.56(bs, 1H);
13C NMR(CDCl
3) δ 23.9,24.5,26.5,27.0,27.2,28.4,34.9,38.2,39.4,45.8,51.2,79.0,87.6; CIMS m/z(% relative intensity) 250(MH+, 100); Ultimate analysis: C
14H
24BNO
2HCl calculated value: C, 58.87, H, 8.82, N, 4.90, Cl, 12.41. measured value: C, 58.40, H, 8.86, N, 4.81, Cl, 12.39.
Hydrochloride (about 4.5M with ether, 200ml) and ethyl acetate (EtoAc) (150ml) make solvent, carry out 29g, the similar reaction of 101mmol scale can obtain the R by 81: 19 mixed: the mixture of S isomer hydrochloride (11.1g, 47%).
Embodiment 11
Utilize that fractionation crystallization obtains (1S, 2S, 3R, 5S)-pinane glycol-tetramethyleneimine-2R-boric acid ester hydrochloride
Method A:
(1.18g 4.13mmol) is dissolved in CH to 60: 40 isomer mixtures that embodiment 10 is obtained
2Cl
2(65ml), heat a little and solution is filtered.Filtrate is diluted with ethyl acetate (65ml), and crystallization begins within one minute.Suspension at room temperature stirred 1-2 hour, collected the solids that forms for the first time, by recording diastereomer ratio (540mg, 46%, R: S ratio 97.1: 2.9) described in the embodiment 9.Solvent is distilled up to most of CH from filtrate
2Cl
2Be removed, then remaining ethyl acetate solution at room temperature stirred the micro white solids (346mg, 29%, the R: S ratio 39.2: 60.8) that spend the night and form for the second time to produce.Primary product Virahol (10ml) recrystallization acquisition 430mg(80% transformation efficiency) the 2-R isomer material (fusing point 269-272 ℃ (decomposition)) of purity>99%.〔α〕
25D+0.70°(C=1.15,MeOH)
1H NMR(CDCl
3): δ 0.83(s, 3H), and 1.14(d, J=11Hz, 1H), 1.29(s, 3H), 1.45(s, 3H), 1.85-2.15(m, 6H), 2.17-2.50(m, 3H), 3.18-3.25(m, 1H), 3.45(bs, 2H), 4.42(dd, J=1.8,8.6Hz, 1H), 8.80(bs, 1H), 10.56(bs, 1H);
13C NMR(CDCl
3) δ 23.9,24.5,26.5,27.0,27.2,28.5,34.9,38.1,39.4,45.8,51.2,79.0,87.8, CIMS m/z(% relative intensity) 250(MH+, 100); Anal.Calcd for C
14H
24BNO
2HCl: C, 58.87, H, 8.82, N, 4.90, Cl, 12.41. measured value: C, 58.64, H, 8.79, N, 4.90, Cl, 12.66.
Method B:
(1S, 2S, 3R, 5S)-isomer mixture (850mg of pinane glycol-tetramethyleneimine-1: 1 ratio of 2RS-borate acidulants, 2.98mmol) suspension in ethyl acetate (60ml) stirred 4 hours under reflux, with the mixture heat filtering and collect the material (541mg, 64%) that the exsiccant solids obtains enrichment R isomer, wherein R: the S ratio is 2: 1.Filtrate evaporation is obtained the material (217mg) of enrichment S isomer, wherein R: the S ratio is 1: 4.The solids that obtains after filtration (500mg) was handled 1.5 hours with ethyl acetate (45ml) with same method, carried out heat filtering again to obtain solids (366mg, 73%), R: S=7: 1.This material uses ethyl acetate (38ml) to handle once more 1.5 hours, and the R of separated solids this moment (287mg, 78%): the S ratio is 97: 3.Its spectral quality is identical with the material that is obtained by the A method.
Embodiment 12
Prepare 1-(1,1-dimethyl ethoxy carbonyl from (1S, 2S, 3R, 5S)-pinane glycol 1-(1,1-dimethyl ethoxy carbonyl)-tetramethyleneimine-2-boric acid ester)-tetramethyleneimine-2-boric acid
To (the 1S that makes by embodiment 8 described methods, 2S, 3R, 5S)-pinane glycol-1-(1,1-dimethyl ethoxy carbonyl)-tetramethyleneimine-2RS-boric acid ester (1.9g, 5.44mmol) add in the solution in acetone (80ml) 0.1M ammonium acetate solution (80ml) and sodium metaperiodate (3.49g, 16.33mmol).Reaction mixture is stirring at room 40 hours, and then with acetone evaporated, residuum is with 2M NaOH solution-treated, this water CH
2Cl
2(2 * 80ml) extractions.With the organic extract liquid drying (Na that merges
2SO
4) and concentrate to produce needed white foam shape solid product (890mg, 76%), its NMR with the material of preparation in embodiment 2 is identical.For analysis purposes is derived boric acid and tetramethyl ethylene ketone.
Embodiment 13
Any pure 1-(1 quite, 1-dimethyl ethoxy carbonyl)-tetramethyleneimine-2RS-boric acid ester
Boric acid (the 890mg that in embodiment 12, produces, 4.14mmol) add quite any alcohol (489mg in the solution in chloroform, 4.14mmol), at room temperature stir to remove after 16 hours and desolvate, residuum is by silica gel column chromatography (hexane/ethyl acetate, 4: 1) carry out purifying, obtain needed white solid product (1.04g, 85%) (fusing point: 73-75 ℃).
1H NMR(CDCl
3): δ 1.18(s, 6H), 1.21(s, 6H), 1.38(s, 9H), 1.57-2.00(m, 4H), 2.98(br s, 1H), 3.27(m, 2H); 13C NMR(CDCl
3): δ 24.3,24.5, and 24.7,24.9,25.3,27.0,27.6,28.4,28.6,43.6,45.8,46.3,78.8,83.2,154.4,154.8; CIMS m/z(% relative intensity) 298(18), 242(100, MH+-tBu), 198(30, MH+-Boc); Ultimate analysis: C
15H
28BNO
4Calculated value: C, 60.62, H, 9.50, N, 4.71. measured value: C, 60.94, H, 9.65, N, 4.88.
Embodiment 14
N-(1,1-dimethyl ethoxy carbonyl)-the valyl tetramethyleneimine of L--2R-boric acid (1S, 2S, 3R, 5S)-the pinane diol ester.
(351.7g is 1.62mol) at CH for tert-butoxycarbonyl (t-Boc)-L-Xie Ansuan
2Cl
2Solution (1.6L) cools off with ice bath, and 0~2 ℃ within 40 minutes with dicyclohexyl carbodiimide (161.8g, CH 0.784mol)
2Cl
2(0.75L) solution adds in the above-mentioned solution.After adding solution was stirred 3.5 hours down at 0~5 ℃, filter out white precipitate and use CH
2Cl
2(0.2L) wash, in the settled solution that obtains, add (1S, the 2S for preparing by embodiment 10 18~20 ℃ (water-bath coolings), 3R, 5S)-(210g 0.735mol) is containing N-methylmorpholine (164g, CH 1.62mol) to pinane glycol tetramethyleneimine-2RS-boric acid ester hydrochloride
2Cl
2Solution (2.0L).Mixture is in stirred overnight at room temperature, and muddy solution filters through a high silicagel column (200~425 order) of 16cm diameter * 2cm, and uses CH
2Cl
2(1.5L) wash.Solvent evaporated is to obtain the oily matter (542g) of high viscosity.This mixture will be cooled off in this oily matter dissolving dry ethyl acetate (0.7L) and in ice bath.The crystallization that filters out formation is at low temperatures also washed with cold ethyl acetate (0.1L).Wet cake transferred in the sherwood oil (0.65L) stirred 1 hour under the room temperature.The white solid thing is filtered, wash and be dried to constant weight to obtain the subject compound (113.4g) (128~130 ℃ of fusing points) of white solid with cold sherwood oil (0.1L).Collect all mother liquors and be concentrated into about 0.8 liter of volume.In refrigerator, place 2 days after-filtration and go out formed solids, handle to obtain beige solid (50.4g) with sherwood oil as stated above.This solids is the mixture of impurity and unwanted diastereomer.Concentrate the mother liquor that obtains above, residuum is (14cm diameter * 60cm on silicagel column; With hexane/ethyl acetate (85: 15) (14L) open up the layer) purifying it.Collect suitable part and handle, collect solids and dry to obtain more required product (18.5g) with filtration method with sherwood oil.Obtain another kind of diastereomer (7.5g) (fusing point 82-83 ℃) simultaneously.Mixing portion that merges and mother liquor obtain extra pure compound (13.5g) by second column purification, obtain 145.4g(44.3% altogether) required diastereomer (128~130 ℃ of fusing points).
1H NMR(CDCl
3): δ 0.83(s, 3H), and 0.91(d, J=6.7Hz, 3H), 0.97(d, J=6.7Hz, 3H), 1.27(s, 3H), 1.35-1.45(m, 1H), 1.39(s, 3H), 1.41(s, 9H), 1.72-2.14(m, 9H), 2.26-2.36(m, 1H), 3.15(dd, J=6.7,10.1Hz, 1H), 3.43-3.51(m, 1H), 3.70-3.81(m, 1H), 4.19-4.28(m, 2H), 5.29(d, J=9.2Hz, 1H);
13C NMR(CDCl
3): δ 17.3,19.2, and 24.0,26.3,27.1,27.2,27.4,28.4,28.6,31.4,33.9,35.5,38.2,39.6,46.7,51.2,56.6,77.8,79.2,85.8,155.9,170.2; CIMS m/z(% relative intensity) 449(MH+, 100), 393(50); Ultimate analysis: C
24H
41BN
2O
5Calculated value: C, 64.28, H, 9.22, N, 6.25. measured value: C, 64.58, H, 9.33, N, 6.52.
Embodiment 15
L-Val-Pyr-2R-boric acid (1S, 2S, 3R, 5S)-pinane diol ester acid maleate
With N-(1; 1-dimethyl ethoxy carbonyl)-L-Val-Pyr-2R-boric acid (1S; 2S; 3R; 5S)-pinane diol ester (248mg; 0.553mmol) join in the solution of anhydrous hydrogen chloride in ethyl acetate of stirring, solvent evaporated is to stay de-protected hydrochloride after 1.5 hours.Residuum is allocated in CH
2Cl
2And between the sodium carbonate solution, organic layer is dry on sal epsom, and organic layer contains the free alkali of subject compound, and it exists with the ring compound form that contains a nitrogen-boron key, is the open loop form but restore after adding acid.Organic solution is filled into toxilic acid, and (64mg, 0.553mmol) in the solution in methyl alcohol (5ml), solvent evaporated stays crystalline residuum (258mg), and its recrystallization in ethyl acetate is obtained subject compound (193mg, 75%)
(145~146 ℃ of fusing points).
1H NMR(CDCl
3): δ 0.84(s, 3H), and 1.08(d, J=6.9Hz, 3H), 1.13(d, J=6.9Hz, 3H), 1.26-1.31(m, 2H), 1.29(s, 3H), 1.38(s, 3H), 1.72-2.15(m, 7H), 2.24-2.38(m, 2H), 3.28(dd, J=6.9,9.4Hz, 1H), 3.38-3.47(m, 1H), 3.73-3.78(m, 1H), 4.14(d, J=5.1Hz, 1H), 4.26(d, J=7.1Hz, 1H), 6.25(s, 2H), 7.5-9.0(v.br, 4H);
13C NMR(CDCl
3): δ 17.0,18.4, and 24.0,26.3,27.0,27.1,28.7,30.0,35.4,38.2,39.5,47.3,51.2,56.6,78.1,86.2,135.6,166.3,169.5; CIMS m/z(% relative intensity) 349(MH+, 100), 197(18); Ultimate analysis: C
23H
37BN
2O
7Calculated value: C, 59.49, H, 8.03, N, 6.03. measured value: C, 59.50, H, 8.13, N, 6.03.
Embodiment 16
L-Val-Pyr-2R-boric acid mesylate
A) ring-L-Val-Pyr-2R-boric acid
(5.0g, 10.8mmol) (1.0%, 60ml) solution in adds and is H the maleate that will obtain by embodiment 15 at dilute acetic acid
-On the Dowex50X2-200 ion exchange resin column of form (3.5cm dark * 4cm diameter), use then acetic acid (1.0%, 14L), water (42L) and solution of ammonium hydroxide (by commodity 0.880 solution that dilutes at 1: 100) this post of wash-out.The pinane glycol can reclaim from center pillar and acidic moiety.Product appears at basic moiety early, with its collection and use CH
2Cl
2(2 * 100ml) wash.With the dry free alkali (174mg, 20%) that also concentrates the parent material that obtains reclaiming with some pinane glycol of organic extract.To form subject compound, there be (1.52g, 66%) (120~130 ℃ of fusing points) in this compound with the ring-type white solid compound form with a nitrogen-boron key with the water lyophilize.
1H NMR(CDCl
3): δ 0.97(d, J=7.0Hz, 3H), 1.06(d, J=7.0Hz, 3H), 1.59-1.80(m, 2H), 1.95-2.03(m, 2H), 2.41-2.51(m, 1H), 2.62-2.69(m, 1H), 3.23-3.32(m, 1H), 3.51-3.58(m have the eclipsed doublet, J=4.2Hz, 2H);
13C NMR(D
2O): δ 19.0,21.7, and 27.3,30.7,29.9,49.6,61.0,170.3; IR(cm
-1) 3400-3314,3221-3108,2961-2872,1637,1452-1369; CIMS m/z(% relative intensity) 375(90, M
2H+-3H
2O), 197(100, MH+-H
2O); Ultimate analysis: C
9H
19BN
2O
3Calculated value: C, 50.50, H, 8.95, N, 13.09. measured value: C, 50.43, H, 8.76, N, 12.93.
B) L-Val-Pyr-2R-boric acid mesylate
Dropwise to the cyclisation boric acid (5.17g that as above makes under nitrogen protection that stirs; 24.16mmol) add methylsulfonic acid (2.32g in the suspension in acetonitrile (190ml); 24.16mmol) solution in acetonitrile (10ml); after dripping in 5 minutes; mixture was at room temperature stirred 2 hours; collect solids with filtration method, with acetonitrile and diethyl ether that its thorough washing is also dry to obtain to be white in color solid subject compound (6.14g, 82%) (179~180 ℃ of fusing points).This material through dimethyl formamide/acetonitrile crystallization once obtains this material (fusing point 181-182 ℃) of 70% yield.
1H NMR(D
2O, phosphoric acid salt, pH2): δ 0.99(d, J=6.8Hz, 3H), 1.09(d, J=6.9Hz, 3H), 1.69-1.75(m, 1H), 1.90-1.99(m, 1H), 2.10-2.14(m, 2H), 2.28-2.35(m, 1H), 2.80(s, 3H), 3.07(dd, J=7.0 and 11.2Hz, 1H), 3.46-3.51(m, 1H), 3.75(t, J=9.0Hz, 1H), 4.14(d, J=5.1Hz, 1H); At 3.53-3.55(m) and 3.83(d, J=6.2Hz) locate also to find cis acid amides rotational isomer;
13C NMR: δ 16.2,18.4,26.9,27.1, and 29.0,38.8,47.9,49.0,57.2,167.2; 16.8,24.3,29.9,57.8,167.5 places find to belong to the peak of cis acid amides rotational isomer; IR(cm
-1) 3387,3000(br), 2972,2655,1646,1370,1197; CIMS m/z(% relative intensity, eg adduct bond) 241(MH+100);
Ultimate analysis: C
10H
23BN
2O
6S
Calculated value: C, 38.72, H, 7.47, N, 9.03.
Measured value: C, 38.65, H, 7.45, N, 8.44.
Embodiment 17
N-(1,1-dimethyl ethoxy carbonyl)-L-Val-Pyr-2R-boric acid
To the N-(1 that presses embodiment 14 preparations that stirs, 1-dimethyl ethoxy carbonyl)-L-Val-Pyr-2R-boric acid (1S, 2S, 3R, 5S)-(1.0g 2.3mmol) adds ammonium acetate solution (60ml to the pinane diol ester in the solution in acetone (75ml), 0.1M) and sodium metaperiodate (1.48g, 6.91mmol), reaction mixture was stirring at room 48 hours, and acetone is removed in evaporation then.CH is handled and used to residuum with 2M sodium hydroxide solution (100ml)
2Cl
2Wash (2 * 50ml).Water layer is acidified to pH3 carefully and uses CH with 2M hydrochloric acid
2Cl
2(4 * 70ml) extractions.The acidic solution organic extract liquid that merges also concentrates to form required white foam shape solid product (700mg, 90%) with dried over sodium sulfate.Through silica gel column chromatography (CH
2Cl
2/ methyl alcohol 9: 1) be further purified and obtain white boric acid solids (449mg, 62%) (fusing point: 82~92 ℃) once more.
1H NMR(CDCl
3): δ 0.95(d, J=5.7Hz, 6H), 1.42(s, 9H), 1.55-1.80(m, 1H) 1.80-2.20(m, 4H), 2.89-3.07(m, 1H), 3.30-3.55(m, 1H), 3.55-3.65(m, 1H), 4.10-4.30(m, 1H), and 5.34(d, J=9.2Hz, 1H);
13C NMR(CDCl
3): δ 18.0,19.1, and 26.3,27.7,28.3,31.2,46.1,52.0,55.7,79.5,155.6,170.8; IR(cm
-1) 3395-3319,2971-2875,1711,1619,1400,1174; CIMS m/z(% relative intensity, eg adduct bond)
341(MH
+,100),285(MH
+-tBu,67),241(MH
+-BOC,21).
Embodiment 18
The valyl tetramethyleneimine of L--2R-borate acidulants
The N-(1 that makes by embodiment 17; 1-dimethyl ethoxy carbonyl)-the valyl tetramethyleneimine of L--2R-boric acid (250mg; 0.796mmol); under the room temperature nitrogen protection with HCl/ ether (4.5M; 20ml) stir 1.5 hours together; solvent is removed in evaporation then, and (3 * 10ml) grind and the ether that at every turn inclines residuum with diethyl ether.With the residuum drying to obtain the solid-state subject compound of white powdery (172mg, 86%) (211~213 ℃ of fusing points).
1H NMR(D
2O, phosphoric acid salt pH2): δ 0.99(d, J=6.9Hz, 3H), 1.09(d, J=7.0Hz, 3H), 1.67-1.76(m, 1H), 1.87-2.01(m, 1H), 2.09-2.15(m, 2H), 2.28-2.35(m, 1H), 3.07(dd, J=7.0 and 11.4 Hz, 1H), 3.48(dt, J=6.7 and 10.3Hz, 1H), 3.73(dt, J=1.7 and 10.2Hz, 1H), 4.14(d, J=5.2Hz, 1H);
13C NMR: δ 16.0,18.3,26.9,27.1, and 28.9,47.9,48.9,57.2,167.3; IR(cm
-1) 3400-2800,3368,2970/2880,1635,1475-1378,1400; CIMS m/z(% relative intensity, eg adduct bond) 241(MH
+, 100).
Embodiment 19
Carry out the valyl tetramethyleneimine of transesterification preparation ring-L--2R-boric acid with phenyl-boron dihydroxide
Will be by the valyl tetramethyleneimine of the L--2R-boric acid (1S of embodiment 15 preparations; 2S; 3R; 5S)-pinane diol ester hydrochloride (500mg; 1.3mmol) (500mg, the solution that is become in the 1M hydrochloric acid (10ml) 2.6mmol) be violent stirring 1 hour at room temperature containing hexane (20ml) and phenyl-boron dihydroxide.Remove hexane with decantation, add more hexane (20ml) then, and mixture was further stirred 30 minutes.Divide each layer of leaving away, the hexane layer of merging is with dried over sodium sulfate and concentrated pinane glycol phenyl-borate (331mg, 99%) with the crystalline solid that obtains being white in color.Water layer is by a Dowex50 ion exchange resin column subsequently, and this post water (20ml) wash-out is used solution of ammonium hydroxide (commodity 0.880 solution of dilution in 1: 100,50ml) wash-out subsequently.Separate basic moiety, lyophilize obtains the free boric acid (230mg, 83%) of white powdered then, and it is identical to analyze the material that itself and embodiment 16a obtain through NMR.
Claims (44)
1, a kind of proline(Pro) of preparation formula VII
The method of boric acid ester
X is a linking group in the formula,
This method comprises:
A) handle the pyrroles with the activatory carbonic acid derivatives, to obtain suc as formula the protected pyrroles of the N-of I
R is C in the formula
1-6Alkyl, C
3-6Cycloalkyl, benzyl, phenyl is by one or more C
1-6The phenyl that alkyl replaces, or trimethyl silyl ethyl,
B) handle the protected intermediates of formula I with lithiation reagent, to obtain the intermediate of formula II
R is as defined above in the formula,
C) with trialkyl borate and the reaction of formula II intermediate, each alkyl can be the straight chain that contains 1-6 carbon atom in this ester, and side chain or cyclic alkyl are used acid-catalyzed hydrolysis then, to obtain the intermediate of formula III
R is as defined above in the formula,
D) with catalytic hydrogenation reduction-type III compound, to obtain the proline(Pro) intermediate of formula IV
R is as defined above in the formula,
E) make formula IV compound with suc as formula the reaction of the glycol of V
X is and identical connection above-mentioned in the formula
Base is to obtain the boric acid ester of formula VI
X is and identical connection base above-mentioned in the formula, and R is as defined above,
F) remove the protecting group on the nitrogen-atoms in the proline(Pro) ring.
2, according to the process of claim 1 wherein in (C) step Chinese style II intermediate and boric acid trimethylammonium ester or the reaction of triethyl ester.
3, according to the process of claim 1 wherein that connecting basic X is 2 to 3 yuan of saturated hydrocarbon chains; Constitute C
5-122 to 3 yuan of saturated hydrocarbon chains of the part of carbocyclic ring system, this member ring systems can contain unsaturated link(age) or condensed ring; Constitute 2 to 3 yuan of hydrocarbon chains of the part of aromatic ring system; Or X is formula-(CH
2) n-NH-(CH
2) group of m-, wherein n and m all can be 2 or 3; Wherein this class group can be unsubstituted or by one or more C
1-3Alkyl or phenyl replaces.
4, according to the process of claim 1 wherein that quite where esterification in (e) step is with the glycol of selecting oneself, alcohol, pyrocatechol, pinane glycol, fourth-2, the 3-glycol, diethanolamine and 1,2-phenylbenzene second-1, the glycol of 2-glycol is finished.
5, according to the method for claim 4, wherein glycol is the pinane glycol of optically active.
6, according to the method for claim 5, the protected pinane diol ester of N-that wherein forms in (e) of claim 1 step further is separated into its diastereomer.
7, according to the method for claim 5, the protected pinane diol ester of N-that wherein forms in (f) of claim 1 step further is separated into its diastereomer.
8, according to the process of claim 1 wherein that R is the tertiary butyl, benzyl, trimethyl silyl ethyl, phenyl, methyl or ethyl.
9, a kind of method of borate proline of preparation formula VII,
X connects base in the formula,
This method comprises:
A) handle the pyrroles with a kind of activatory carbonic acid derivatives, with the protected pyrroles of N-of acquisition formula I,
R is C in the formula
1-6Alkyl, C
3-6Cycloalkyl, benzyl, phenyl is by one or more C
1-6
The phenyl that alkyl replaces, or trimethyl silyl ethyl,
B) handle formula I protected intermediates with lithiation reagent, obtaining the intermediate of formula II,
R is as defined above in the formula,
C) with trialkyl borate and the reaction of formula II intermediate, each alkyl can be the straight chain that contains 1~6 carbon atom in this ester, and side chain or cyclic alkyl are used acid-catalyzed hydrolysis subsequently, to obtain the intermediate of formula III
R is as defined above in the formula,
D) glycol of formula V and formula III compound are reacted
V is to connect base in the formula,
To obtain the boric acid ester of formula III A
R is as defined above in the formula,
E) ester that is generated through the catalytic hydrogenation reduction is to obtain the proline(Pro) intermediate of formula VI
F) remove protecting group from the proline(Pro) ring nitrogen.
10, according to the method for claim 9, wherein in (c) step, formula II intermediate and boric acid trimethylammonium ester or triethyl ester react.
11, according to the method for claim 9, wherein connecting basic X is 2 to 3 yuan of saturated hydrocarbon chains; Constitute C
5-122 to 3 yuan of saturated hydrocarbon chains of the part of carbocyclic ring system, this member ring systems can contain unsaturated link(age) or condensed ring; Constitute 2 to 3 yuan of hydrocarbon chains of the part of aromatic ring system; Or X is formula-(CH
2) n-NH-(CH
2) group of m-, wherein n and m each naturally 2 or 3; Wherein this class group can be unsubstituted or by one or more C
1-3Alkyl or phenyl replaces.
12, according to the method for claim 9, wherein the esterification in (e) step is to comprise ethylene glycol, quite which alcohol, pyrocatechol, pinane glycol, fourth-2 with being selected from, 3-glycol, diethanolamine and 1, and 2-phenylbenzene second-1, the glycol of 2-glycol is finished.
13, according to the method for claim 12, glycol wherein is the pinane glycol of optically active.
14, according to the method for claim 13, the protected pinane diol ester of N that wherein forms in (e) of claim 9 step further is separated into its diastereomer.
15, according to the method for claim 13, the protected pinane diester of N that wherein forms in (f) of claim 9 step further is separated into its diastereomer.
16, according to the method for claim 9, wherein R is the tertiary butyl, benzyl, trimethyl silyl ethyl, phenyl, methyl or ethyl.
17, a kind of method of preparation formula IV intermediate
This method comprises:
A) handle the pyrroles with the activatory carbonic acid derivatives, with the protected pyrroles of the N-that obtains the formula I,
R is C in the formula
1-6Alkyl, C
3-6Cycloalkyl, benzyl, phenyl is by one or more C
1-6The phenyl that alkyl replaces, or trimethyl silyl ethyl,
B) handle the protected intermediates of formula I with lithiation reagent, obtaining formula II intermediate,
R is as defined above in the formula,
C) with the intermediate reaction of trialkyl borate and formula II, each alkyl can be straight chain, side chain or the cycloalkyl that contains 1-6 carbon atom in this ester, uses acid-catalyzed hydrolysis subsequently, with the intermediate of acquisition formula III,
R is as defined above in the formula,
D) through the compound of catalytic hydrogenation reduction-type III, to obtain the proline(Pro) intermediate of formula IV.
18, a kind of method of intermediate of preparation formula IV
This method comprises:
A) handle tetramethyleneimine with acylating reagent, with the protected tetramethyleneimine of acquisition formula VIII,
R is C in the formula
1-6Alkyl, C
3-6Cycloalkyl, benzyl, phenyl are by one or more C
1-6Phenyl or trimethyl silyl ethyl that alkyl replaces,
B) handle the compound of formula VIII with lithiation reagent, to obtain the compound of formula IX
R is as defined above in the formula,
C) with the compound reaction of trialkyl borate and formula IX, each alkyl contains straight chain, side chain or the cycloalkyl of 1-6 carbon atom in this ester,
D) product of hydrolysis abovementioned steps is to obtain the compound of formula IV.
19, according to the method for claim 18, wherein in (c) step Chinese style IX intermediate and boric acid trimethylammonium or the reaction of triethyl ester.
20, the intermediate of formula III
Wherein R is C
1-6Alkyl, C
3-6Cycloalkyl, benzyl, phenyl are by one or more C
1-6
The phenyl that alkyl replaces, or trimethyl silyl ethyl.
21,1-(1,1-dimethyl ethoxy carbonyl)-pyrroles-2-boric acid.
22, a kind of compound that is selected from down group comprises
(1S, 2S, 3R, 5S)-the pinane glycol
1-(1,1-dimethyl ethoxy carbonyl)-tetramethyleneimine-2S-boric acid ester;
(1S, 2S, 3R, 5S)-the pinane glycol
1-(1,1-dimethyl ethoxy carbonyl)-tetramethyleneimine-2R-boric acid ester; (1R, 2R, 3S, 5R)-the pinane glycol
1-(1,1-dimethyl ethoxy carbonyl)-tetramethyleneimine-2S-boric acid ester; (1R, 2R, 3S, 5R)-the pinane glycol
1-(1,1-dimethyl ethoxy carbonyl)-tetramethyleneimine-2R-boric acid ester.
23, a kind of compound that is selected from down group comprises
(1S, 2S, 3R, 5S)-pinane glycol tetramethyleneimine-2S-boric acid ester hydrochloride;
(1S, 2S, 3R, 5S)-pinane glycol tetramethyleneimine-2R-boric acid ester hydrochloride;
(1R, 2R, 3S, 5R)-pinane glycol tetramethyleneimine-2S-boric acid ester hydrochloride;
(1R, 2R, 3S, 5R)-pinane glycol tetramethyleneimine-2R-boric acid ester hydrochloride.
24, a kind of compound that is selected from down group comprises
(1S, 2S, 3R, 5S)-and pinane glycol 1-(1,1-dimethyl ethoxy carbonyl)-pyrroles-2-boric acid ester; With
(1R, 2R, 3S, 5R)-and pinane glycol 1-(1,1-dimethyl ethoxy carbonyl)-pyrroles-2-boric acid ester.
25, a kind of removing from boric acid ester in the method as the pinane glycol of protectiveness ester group, this method comprise with a kind of having cracking 1, this class boric acid ester of the oxidizer treatment of 2-glycol ability.
26, according to the method for claim 25, wherein said oxygenant is a sodium metaperiodate.
27, a kind of pinane glycol of from formula X compound, removing as the protectiveness ester group
R in the formula
2Be a blocking group, R
3Be naturally occurring amino acid whose side chain, it can have suitable protecting group; Or the method for from formula XI compound, removing the pinane glycol,
R in the formula
2Be as defined above, this method comprises with a kind of having cracking 1, this class boric acid ester of the oxidizer treatment of 2-glycol ability.
28, according to the method for claim 27, wherein said oxygenant is a sodium metaperiodate.
29, a kind of method of from boric acid ester, removing as the pinane glycol of protectiveness ester group with free amine; this method comprises that the aqueous solution with this class boric acid ester is added on the cation exchange resin column; water and this post of dilute acid solution wash-out to be to remove the pinane glycol, at last with this post of dilute alkaline aqueous solution wash-out to remove free boric acid product.
30, according to the method for claim 29, wherein said column packing is a kind of strongly acidic cation-exchange.
31, a kind of method of from the compound of formula XI, removing as the pinane glycol of protectiveness ester group
R in the formula
3It is naturally occurring amino acid whose side chain; it can have suitable protecting group; this method comprises this class boric acid ester aqueous solution is added on the cation exchange resin column; water and dilute acid solution wash-out to be to remove the pinane glycol, at last with this post of dilute alkaline aqueous solution wash-out to remove free boric acid product.
32, according to the method for claim 31, wherein said column packing is a kind of strongly acidic cation-exchange.
34, N-(1,1-dimethyl ethoxy carbonyl)-the valyl tetramethyleneimine of L--2R-boric acid (1S, 2S, 3R, 5S)-the pinane diol ester.
35, the intermediate of formula XI
Protecting group-O-X-O is derived from the pinane glycol in the formula, and R wherein
3Be the natural amino acid whose side chain that exists, it optionally has suitable protecting group.
36, the valyl tetramethyleneimine of L--2R-boric acid (1S, 2S, 3R, 5S)-pinane diol ester or its salt.
37, a kind of method of borate proline of preparation formula VII
X connects base in the formula, and this method comprises:
A) handle tetramethyleneimine with acylating reagent, to obtain the protected tetramethyleneimine of formula VIII
Wherein R is C
1-6Alkyl, C
3-6Cycloalkyl, benzyl, phenyl are by one or more C
1-6The phenyl that alkyl replaces, or trimethyl silyl ethyl,
B) handle the compound of formula VIII with lithiation reagent, to obtain the compound of formula IX
R such as preceding definition in the formula,
C) compound of trialkyl borate and formula IX is reacted, each alkyl all can be straight chain, side chain or the cycloalkyl that contains 1~6 carbon atom in this ester
D) product in the hydrolysis abovementioned steps is to obtain the compound of formula IV
E) with the glycol of formula V and the compound reaction of formula IV
X is the connection base identical with top described person in the formula, to obtain the boric acid ester of formula VI
X carries identical connection base with top in the formula, and R is as defined above,
F) remove the protecting group on the nitrogen-atoms in the proline(Pro) ring.
38, according to the method for claim 37, wherein in intermediate and the boric acid trimethylammonium ester or the reaction of triethyl ester of (C) step Chinese style IX.
39, according to the method for claim 37, wherein linking group X is 2 to 3 yuan of saturated hydrocarbon chains; Constitute C
5-122 to 3 yuan of saturated hydrocarbon chains of the part of carbocyclic ring system, this member ring systems alternative has unsaturated link(age) or condensed ring; Constitute 2 to 3 yuan of hydrocarbon chains of the part of aromatic ring system, or X is formula-(CH
2) n-NH-(CH
2) group of m-, wherein n and m all 2 or 3; Wherein this class group can be unsubstituted or by one or more C
1-3Alkyl or phenyl replaces.
40, according to the method for claim 37, wherein the esterification in (e) step is to comprise ethylene glycol with being selected from, any alcohol quite, and pyrocatechol, the pinane glycol, fourth-2, the 3-glycol, diethanolamine and 1,2-phenylbenzene second-1, the glycol of 2-glycol is finished.
41, according to the method for claim 40, glycol wherein is the pinane glycol of optically active.
42, according to the method for claim 41, the protected pinane diol ester of N that wherein forms in (e) of claim 37 step further is separated into its diastereomer.
43, according to the method for claim 41, the protected pinane diol ester of N that wherein forms in (f) of claim 37 step further is separated into its diastereomer.
44, according to the method for claim 37, wherein R is the tertiary butyl, benzyl, trimethyl silyl ethyl, phenyl, methyl or ethyl.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79614891A | 1991-11-22 | 1991-11-22 | |
US796,148 | 1991-11-22 | ||
US93619892A | 1992-08-26 | 1992-08-26 | |
US936,198 | 1992-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1073946A true CN1073946A (en) | 1993-07-07 |
Family
ID=27121696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN92113215A Pending CN1073946A (en) | 1991-11-22 | 1992-11-23 | The method for preparing borate proline |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0641347A1 (en) |
JP (1) | JPH07501078A (en) |
CN (1) | CN1073946A (en) |
AU (1) | AU661362B2 (en) |
CA (1) | CA2123128A1 (en) |
CZ (1) | CZ124494A3 (en) |
FI (1) | FI942345A (en) |
HU (1) | HUT67937A (en) |
IL (1) | IL103817A0 (en) |
MX (1) | MX9206628A (en) |
NO (1) | NO941905L (en) |
NZ (1) | NZ245207A (en) |
PT (1) | PT101079A (en) |
SI (1) | SI9200332A (en) |
SK (1) | SK59294A3 (en) |
TW (1) | TW232697B (en) |
WO (1) | WO1993010127A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1331835C (en) * | 2005-10-18 | 2007-08-15 | 武汉大学 | Preparation method of optically active beta-hydroxy ketone |
CN103450241A (en) * | 2008-06-17 | 2013-12-18 | 米伦纽姆医药公司 | Borate compound and medicine composition thereof |
CN108047257A (en) * | 2017-12-17 | 2018-05-18 | 沧州普瑞东方科技有限公司 | A kind of preparation process of chirality N-BOC- pyrrolidines -2- boric acid |
CN110452258A (en) * | 2019-09-03 | 2019-11-15 | 上海馨远医药科技有限公司 | A kind of preparation method of dipeptides valine Boroproline salt |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6825169B1 (en) | 1991-10-22 | 2004-11-30 | Trustees Of Tufts College | Inhibitors of dipeptidyl-aminopeptidase type IV |
US5965532A (en) * | 1996-06-28 | 1999-10-12 | Trustees Of Tufts College | Multivalent compounds for crosslinking receptors and uses thereof |
US6100234A (en) | 1997-05-07 | 2000-08-08 | Tufts University | Treatment of HIV |
US6040145A (en) | 1997-05-07 | 2000-03-21 | Tufts University | Potentiation of the immune response |
KR100458403B1 (en) | 1997-09-29 | 2004-11-26 | 포인트 써러퓨틱스, 인크. | Stimulation of Hematopoietic Cells in vitro |
EP1075266A1 (en) | 1998-05-04 | 2001-02-14 | Point Therapeutics, Inc. | Hematopoietic stimulation |
PT1084129E (en) | 1998-06-05 | 2003-06-30 | Point Therapeutics Inc | BOROPROLINE CYCLIC COMPOUNDS |
US6979697B1 (en) | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
WO2001062266A2 (en) * | 2000-02-25 | 2001-08-30 | Novo Nordisk A/S | Use of dpp-iv inhibitors for the treatment of diabetes |
AU2003218969A1 (en) * | 2002-02-01 | 2003-09-02 | Probiodrug Ag | Modulation of t lymphocytes using dp iv inhibitors |
US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7674913B2 (en) | 2003-11-12 | 2010-03-09 | Phenomix Corporation | Heterocyclic boronic acid compounds |
US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
CN1905876B (en) | 2003-11-17 | 2010-06-09 | 诺瓦提斯公司 | Use of dipeptidyl peptidase IV inhibitors |
EP2165703A3 (en) | 2004-01-20 | 2012-03-28 | Novartis Pharma AG | Direct compression formulation and process |
TW200604137A (en) | 2004-04-27 | 2006-02-01 | Wyeth Corp | Coupling process for generating reactive boron-containing derivatives of n-substituted pyrrole-2-carbonitriles to produce biaryls |
DOP2006000008A (en) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1 |
EP1943257A2 (en) | 2005-05-19 | 2008-07-16 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
EP1973548A4 (en) | 2005-12-19 | 2010-02-24 | Tufts College | Soft protease inhibitors and pro-soft forms thereof |
EP1971862B1 (en) | 2006-04-11 | 2010-11-10 | Arena Pharmaceuticals, Inc. | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual |
PE20071221A1 (en) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS |
EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
AR077642A1 (en) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME |
EP2556056A1 (en) | 2010-04-06 | 2013-02-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
KR101871011B1 (en) | 2010-09-22 | 2018-06-25 | 아레나 파마슈티칼스, 인크. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
US9523687B2 (en) | 2014-02-28 | 2016-12-20 | Institut Pasteur | Levels of CXCL 10/IP-10 forms and soluble CD26/DPPIV activity as early predictive biomarkers for HIV/SIV associated mucosal inflammation and progression towards AIDS |
WO2015179443A1 (en) | 2014-05-20 | 2015-11-26 | Millennium Pharmaceuticals. Inc. | Boron-containing proteasome inhibitors for use after primary cancer therapy |
EA201791982A1 (en) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | METHODS FOR TREATING A NON-ALCOHOLIC FAT LIVER DISEASE AND / OR LIPODYSTROPHY |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
CN110996951A (en) | 2017-04-03 | 2020-04-10 | 科赫罗斯生物科学股份有限公司 | PPAR gamma agonists for the treatment of progressive supranuclear palsy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935493A (en) * | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
JPH05508624A (en) * | 1990-04-14 | 1993-12-02 | ニュー イングランド メデカル センター ホスピタルズ インク | Dipeptidyl-aminopeptidase type 4 inhibitor |
GB9017694D0 (en) * | 1990-08-13 | 1990-09-26 | Sandoz Ltd | Improvements in or relating to organic chemistry |
-
1992
- 1992-11-18 MX MX9206628A patent/MX9206628A/en unknown
- 1992-11-19 PT PT101079A patent/PT101079A/en not_active Application Discontinuation
- 1992-11-19 EP EP92925238A patent/EP0641347A1/en not_active Withdrawn
- 1992-11-19 CZ CZ941244A patent/CZ124494A3/en unknown
- 1992-11-19 JP JP5509442A patent/JPH07501078A/en active Pending
- 1992-11-19 SI SI19929200332A patent/SI9200332A/en unknown
- 1992-11-19 CA CA002123128A patent/CA2123128A1/en not_active Abandoned
- 1992-11-19 SK SK592-94A patent/SK59294A3/en unknown
- 1992-11-19 AU AU31368/93A patent/AU661362B2/en not_active Expired - Fee Related
- 1992-11-19 WO PCT/US1992/009845 patent/WO1993010127A1/en not_active Application Discontinuation
- 1992-11-19 HU HU9401350A patent/HUT67937A/en unknown
- 1992-11-20 NZ NZ24520792A patent/NZ245207A/en unknown
- 1992-11-20 IL IL103817A patent/IL103817A0/en unknown
- 1992-11-20 TW TW081109304A patent/TW232697B/zh active
- 1992-11-23 CN CN92113215A patent/CN1073946A/en active Pending
-
1994
- 1994-05-20 FI FI942345A patent/FI942345A/en not_active Application Discontinuation
- 1994-05-20 NO NO941905A patent/NO941905L/en unknown
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1331835C (en) * | 2005-10-18 | 2007-08-15 | 武汉大学 | Preparation method of optically active beta-hydroxy ketone |
CN103450241A (en) * | 2008-06-17 | 2013-12-18 | 米伦纽姆医药公司 | Borate compound and medicine composition thereof |
CN103467565A (en) * | 2008-06-17 | 2013-12-25 | 米伦纽姆医药公司 | Boronate ester compounds and pharmaceutical compositions thereof |
CN103497232A (en) * | 2008-06-17 | 2014-01-08 | 米伦纽姆医药公司 | Boronate ester compounds and pharmaceutical compositions thereof |
CN108047257A (en) * | 2017-12-17 | 2018-05-18 | 沧州普瑞东方科技有限公司 | A kind of preparation process of chirality N-BOC- pyrrolidines -2- boric acid |
CN110452258A (en) * | 2019-09-03 | 2019-11-15 | 上海馨远医药科技有限公司 | A kind of preparation method of dipeptides valine Boroproline salt |
CN110452258B (en) * | 2019-09-03 | 2021-01-01 | 上海馨远医药科技有限公司 | Preparation method of dipeptide valine boron proline salt |
WO2021043187A1 (en) * | 2019-09-03 | 2021-03-11 | 上海馨远医药科技有限公司 | Method for preparing boron salt of dipeptide of valine-proline |
Also Published As
Publication number | Publication date |
---|---|
NO941905L (en) | 1994-07-14 |
FI942345A0 (en) | 1994-05-20 |
PT101079A (en) | 1994-02-28 |
NZ245207A (en) | 1994-07-26 |
NO941905D0 (en) | 1994-05-20 |
SK59294A3 (en) | 1995-02-08 |
AU3136893A (en) | 1993-06-15 |
JPH07501078A (en) | 1995-02-02 |
HUT67937A (en) | 1995-05-29 |
SI9200332A (en) | 1993-06-30 |
WO1993010127A1 (en) | 1993-05-27 |
AU661362B2 (en) | 1995-07-20 |
TW232697B (en) | 1994-10-21 |
HU9401350D0 (en) | 1994-08-29 |
MX9206628A (en) | 1993-05-01 |
FI942345A (en) | 1994-05-20 |
EP0641347A1 (en) | 1995-03-08 |
CZ124494A3 (en) | 1995-07-12 |
IL103817A0 (en) | 1993-04-04 |
CA2123128A1 (en) | 1993-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1073946A (en) | The method for preparing borate proline | |
JP6193960B2 (en) | Synthesis of boronic acid esters and boronic acid compounds | |
US5384410A (en) | Removal of boronic acid protecting groups by transesterification | |
CN1022412C (en) | Method for preparing urethane-protected amino acid-N-carboxyanhydrides | |
AU695530B2 (en) | Synthesis of taxol, analogs and intermediates with variable a-ring side chains | |
JPH03218380A (en) | Chiral compound | |
Aguilera et al. | Synthesis of diaminosuberic acid derivatives via ring-closing alkyne metathesis | |
WO2017003721A1 (en) | Process for the preparation of lisdexamfetamine and related derivatives | |
Pirkle et al. | Separation of some enantiomeric di-and tripeptides on chiral stationary phases | |
Walkup et al. | Silicon-containing amino acids and peptides. Asymmetric synthesis of (trialkylsilyl) alanines | |
JP2005509028A (en) | Process for the synthesis of aspartic and glutamic acid derivatives and their diazoketone intermediates | |
Barnes et al. | A highly diastereoselective vinylogous Mannich condensation and 1, 4-conjugate addition of (Z)-propenyl cuprate in the synthesis of an influenza neuraminidase inhibitor | |
Fehrentz et al. | The use of N‐urethane‐protected N‐carboxyanhydrides (UNCAs) in amino acid and peptide synthesis | |
US5543526A (en) | 1-amino-4-(1H-imidazole)- aminobutaneboronic acid derivatives, their preparation and use as synthetic intermediates | |
KR0154963B1 (en) | Improved process for the preparation of asymetric urea and carbamate | |
Tanaka et al. | Catalytic dehydrogenative N-((triisopropylsilyl) oxy) carbonyl (Tsoc) protection of amines using iPr 3 SiH and CO 2 | |
Zhang et al. | Synthesis of optically active C-allylglycine derivatives and conversion into isoquinolones | |
JP7244921B2 (en) | Amino acid-type acylborane and method for producing the same | |
CN1121410C (en) | Process for preparation of N-methyl-D-phenylalanyl-N-[1-[3-[(aminoiminomethyl)-amino] propyl]-3,3-difluoro-2-oxohexyl]-L-prolinamide | |
CA3156019A1 (en) | Method for producing peptide compound | |
JPH0641443B2 (en) | Method for producing optically active amino acid | |
KR20010068029A (en) | Lipase-mediated stereoslective hydrolysis of aziridine-2-carboxylates | |
CN87100769A (en) | Have 2-[2-[N, two (2-chloroethyl) the phosphinylidyne diamino oxygen bases of N-] ethyl] novel heterocyclic compound of group | |
WO2013178682A2 (en) | Multicomponent process for the preparation of bicyclic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |